2211985-36-1

Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases[1][2][3].

[1] James S Castleman, et al. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021 Feb;192(3):425-432. DOI:10.1111/bjh.17041
[2] Ling L E, et al. Selective targeting of FcRn and IgG clearance by nipocalimab preserves key immune functions. Hematology, Transfusion and Cell Therapy, 2022, 44: S13.
[3] Marinos C Dalakas, et al. The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286421997381. DOI:10.1177/1756286421997381